Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of March 2010, specifically dated March 2, 2010. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a new issue of securities and an application for quotation on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing details a specific capital event rather than providing a full financial statement. Key metrics include:
- Securities Issued: 245,000 Ordinary Fully Paid Shares.
- Issue Price: AUD$ Nil (issued at no cost).
- Total Quoted Securities: 234,045,871 Ordinary Shares (including the new issue).
- Unquoted Securities: Multiple classes of unlisted options exist, totaling over 24 million options with various exercise prices (ranging from $Nil to AUD$0.50) and expiry dates.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The primary material change is the increase in the company's share capital by 245,000 ordinary shares. These shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act. The issuance consists of two tranches: 165,000 shares issued under Employee Incentive Schemes and Consulting Agreements, and 80,000 shares resulting from the exercise of previously issued options (exercised at $Nil consideration).
Guidance, Outlook, and Risks
Management Commentary: The company intends to apply to the ASX for quotation of the newly issued shares. The new shares rank equally in all respects with existing ordinary shares from the date of allotment. The dividend policy remains unchanged.
Risks and Contingencies: The filing includes standard warranties to the ASX that the issue complies with the law, is not for an illegal purpose, and that no person has a right to return the securities under specific sections of the Corporations Act. The company warrants that an offer of these securities for sale within 12 months will not require further disclosure under specific sections of the Corporations Act.
Important Facts for Investor Verification
- Verify the total number of outstanding shares (234,045,871) and the dilution impact of the 245,000 new shares issued at $Nil.
- Confirm the details of the unlisted options (over 24 million) and their potential dilution upon exercise, noting the mix of $Nil and priced options.
- Check the status of the ASX quotation application for the new shares.
- Review the Employee Incentive Scheme terms to understand the conditions under which the $Nil shares were issued.